Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light of evolving business conditions. This modest downward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback